Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company reports on the results of the Annual Meeting of Shareholders held on May 1, 2018. The document details the voting outcomes for director elections, executive compensation, auditor ratification, and shareholder proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Director Elections (Item 1)
Shareholders elected all 12 nominees to serve as directors until the 2019 Annual Meeting. Voting results varied by nominee:
- Strongest Support: Karen H. Vousden, Ph.D. (1,141,846,830 For votes).
- Lowest Support: Vicki L. Sato, Ph.D. (1,095,622,608 For votes; 39,040,380 Against votes).
- Broker Non-Votes: 278,783,707 shares were recorded as broker non-votes for all director nominees.
Executive Compensation (Item 2)
The advisory vote to approve the compensation of named executive officers was approved.
- For: 1,091,784,630
- Against: 50,001,228
- Abstain: 7,762,774
Auditor Ratification (Item 3)
Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2018.
- For: 1,375,338,345
- Against: 48,726,041
- Abstain: 4,267,953
Shareholder Proposals (Items 4 & 5)
Two shareholder proposals were defeated:
- Drug Pricing Disclosure: A proposal to disclose how risks related to public concern over drug pricing strategies are incorporated into incentive compensation plans was not approved (248,628,516 For vs. 848,228,941 Against).
- Special Meeting Threshold: A proposal to lower the share ownership threshold to call special shareholder meetings was not approved (478,487,300 For vs. 663,579,776 Against).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, or specific risk factors beyond the context of the shareholder proposals regarding drug pricing and meeting thresholds.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the quorum status at the May 1, 2018 meeting to contextualize the vote totals.
- Review the specific "Against" vote percentages for directors, particularly Vicki L. Sato and Michael Grobstein, to assess shareholder sentiment on board composition.
- Confirm the implications of the rejected shareholder proposal regarding drug pricing disclosure on future corporate governance policies.
- Check subsequent filings for the official appointment of the newly elected directors and the finalized audit engagement with Deloitte & Touche LLP.